Fresenius demonstrated strong performance and raised revenue guidance due to robust growth in key segments like Kabi and Biopharma. However, challenges remain, particularly in China and with currency and tariff headwinds. The sentiment reflects a cautiously optimistic outlook, balancing strong achievements with ongoing challenges.

Company Guidance

During the Fresenius earnings call for the second quarter of fiscal year 2025, the company reported strong financial performance, highlighted by an 8% growth in core EPS and a notable 10% increase in core EPS for the first half of the year. The company's full-year organic revenue guidance was raised from 4%-6% to 5%-7%, driven by robust top-line growth. Fresenius Kabi's EBIT margin was reported at 16.4%, and Helios demonstrated solid organic growth of 5%. The company's strategic initiatives, including the #FutureFresenius program, are contributing to increased profitability and margin expansion. The call also underscored the company's focus on sustainability, reflected in an improved ISS ESG rating. Additionally, the company highlighted its positive progress in the biopharma segment and successful new product launches in the U.S. and Europe. Despite macroeconomic volatility and geopolitical tensions, Fresenius remains confident in its strategic direction and financial outlook.

Guidance Raise and Resilient Performance

Fresenius raised its full-year organic revenue guidance from 4%-6% to 5%-7% due to strong top-line growth. The company reported an 8% core EPS growth, with 10% growth in the first half of the year.

Strong Kabi Performance

Kabi achieved a 16.4% EBIT margin, driven by strong performance in IV generics and fluids, and biosimilars. The segment launched 6 new IV generic products in the U.S. and reported 40% organic growth in its cell and gene therapy segment.

Biopharma Achievements

Fresenius Kabi launched a denosumab biosimilar in the U.S. and received EU regulatory approval. The biosimilar Tyenne gained 24% market share in EU5 and was approved in Brazil.

Helios Strategic Advancements

Helios continued its clustering strategy in Germany and was part of a government-approved EUR 4 billion financial support for hospitals.

Fresenius SE & Co (FSNUY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

FSNUY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	0.22 / -	0.185	―	―	―
Aug 06, 2025	2025 (Q2)	0.22 / 0.25	0.218	15.14% (+0.03)
May 07, 2025	2025 (Q1)	0.21 / 0.25	0.204	21.08% (+0.04)
Feb 26, 2025	2024 (Q4)	0.18 / 0.20	0.189	4.23% (<+0.01)
Nov 06, 2024	2024 (Q3)	0.18 / 0.18	0.162	14.20% (+0.02)
Jul 31, 2024	2024 (Q2)	0.19 / 0.22	0.185	17.84% (+0.03)
May 08, 2024	2024 (Q1)	0.19 / 0.20	0.189	7.94% (+0.01)
Feb 21, 2024	2023 (Q4)	0.20 / 0.19	0.211	-10.43% (-0.02)
Nov 02, 2023	2023 (Q3)	0.16 / 0.16	0.17	-4.71% (>-0.01)
Aug 02, 2023	2023 (Q2)	0.17 / 0.18	0.203	-8.87% (-0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

FSNUY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$11.98	$12.10	+1.00%
May 07, 2025	$11.90	$12.09	+1.60%
Feb 26, 2025	$9.45	$10.07	+6.56%
Nov 06, 2024	$9.08	$9.18	+1.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Fresenius SE & Co (FSNUY) report earnings?

Fresenius SE & Co (FSNUY) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).

What is Fresenius SE & Co (FSNUY) earnings time?

Fresenius SE & Co (FSNUY) earnings time is at Nov 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is FSNUY EPS forecast?

FSNUY EPS forecast for the fiscal quarter 2025 (Q3) is 0.22.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing